SGLT-2i: Preserving the kidneys and protecting the heart

01 Aug 2021
During the EMPIRE Summit sponsored by Boehringer Ingelheim, two distinguished speakers shared their insights into the evolving treatment landscape of DKD. Topics discussed include the role of SGLT-2iin fulfilling the unmet needs in DKD management and how evidence of their cardio renal-protective effects have altered clinical practice guidelines globally. 

Related MIMS Drugs

Editor's Recommendations